Circulating tumor cells (CTC) play an important role in tumor spread and metastasis, which ultimately leads to the death of most cancers. Techniques for identifying and counting CTC from the blood of cancer patients have established CTC as important clinical biomarkers for cancer diagnosis and prognosis. CTC have great potential as non-invasive continuous liquid biopsy techniques that may be more representative of the accuracy of individual patient malignancies than traditional tissue biopsy with space and time constraints. Once CTC can be used as biomarkers for the precise management of patients with urinary tumors and for the discovery of new therapeutic agents, the clinical application of CTC will be fully realized and will benefit from a wide range of cancer patient.